Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.

Jessie KittleRenato Deláscio LopesMingyan HuangMarsha L MarquessMatthew D WilsonJohn AscherAlok KrishenVic HasselbladBrad J KollsMatthew T RoeDarren K McGuireStuart D RussellKenneth W Mahaffey

Published in: Clinical cardiology (2017)

CV events in bupropion clinical trials for smoking cessation were uncommon, with no observed increase among subjects assigned to bupropion vs placebo. However, this effort was limited by a paucity of quality data.

Keyphrases

smoking cessation
clinical trial
replacement therapy
quality improvement
electronic health record
cross sectional
double blind
phase iii
big data
phase ii
deep learning
artificial intelligence
data analysis